feed,title,long_url,short_url
Benzinga,"FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol",https://benzinga.com/general/biotech/22/12/30131991/fda-allows-bluebird-bio-to-resume-sickle-cell-disease-studies-in-patients-below-18-with-changed-p,https://da.gd/tcOOP
Benzinga,"Lennar Has To Cut Costs Despite Promising Demand To Weather Economic Uncertainty, Says Analyst",https://benzinga.com/analyst-ratings/analyst-color/22/12/30132567/lennar-has-to-cut-costs-despite-promising-demand-to-weather-economic-uncertainty-sa,https://da.gd/kZxBT
